secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001213900-25-105599
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea activates UAB site for Phase 1/1b PAS-004 NF1 trial; platinum sponsor of symposium
--------------------------------------------------------------------------------

- New U.S. clinical site at University of Alabama at Birmingham activated for ongoing Phase 1/1b PAS-004 trial in adult NF1 patients; enrollment starts immediately.
- PAS-004 is a next-generation macrocyclic oral MEK inhibitor being studied for symptomatic, inoperable plexiform neurofibromas.
- Pasithea named Platinum Sponsor of the 2025 NF Caregivers Symposium at UAB on November 8, 2025.
- CEO Tiago Reis Marques highlighted UAB's deep NF1 expertise and commitment to advancing care.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025105599/0001213900-25-105599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390025105599/ea0263823-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-105599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer